skip to main content
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

Products

もっと見る

もっと見る

34 Total results for product and free and sample content found

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

In Vivo Outlook 2021 Report

08 Oct 2021

In Vivo Outlook 2021 Report

The highly anticipated Outlook 2022 report from Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information. 

Topic Deals BioPharmaceutical Business Strategies

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

By Dorothee Schramm and Katie von der Weid 27 Nov 2020

effective-relief

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

Topic Coronavirus Business Strategies Deals

Generics Bulletin: ジェネリック&バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

27 Nov 2020

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deals

Generics Bulletin: ジェネリック&バイオシミラーニュース

Biocon Biologics Gets True North Investment

By Vibha Ravi 27 Nov 2020

Biocon_Biologics_Gets_True_North_Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deals Strategy

Generics Bulletin: ジェネリック&バイオシミラーニュース

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

2020’s Most Significant Cancer Deals

21 Oct 2020

2020’s Biggest Deals at a Glance

Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.    

Topic Cancer Deals

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。


新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。

お問合せの際はフォームまたは下記メールアドレスをご利用頂くか、営業担当者の携帯電話までご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
サイトライン(旧ファーマインテリジェンス)
Eメール:
inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。